eli lilly glp 1 stock analysis has climbed 394% in five years. Novo Nordisk is essentially flat. The GLP-1 trade was never a basket. $LLY $NVO Eli Lilly Q1 2026 Earnings

46 On the other hand, some experiments seem to confirm direct hepatic effects of GLP-1RA

And while its often blamed on fat loss alone, theres another key factor: collagen loss

Why it works better for many people than semaglutide: Better blood sugar control More consistent fat loss Less stalling during weight loss Retatrutide: Appetite Control + Metabolism on Turbo Mode What it targets: GLP-1 + GIP + Glucagon This is the triple-threat option What does glucagon do for weight loss

Jastreboff, L

We know next to nothing about how these drugs may be impacting people with higher levels of food restriction, which is risky considering how common these medications are and how easy it is to access them

Most peptides don't require this